In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran Roy Baynes M.D., Ph.D. appointed as independent, non-exe ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Discover the latest April 2025 update on Dow Dogs! Learn about top investment picks, forecasted gains, and market corrections ...

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...

The Office of Workforce Strategy and Development announced today the members of Vermont’s new State Workforce Development Board (SWDB), which includes business owners, workforce experts, municipal ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Merck has been raising its R&D budget by a healthy ... Perlmutter is taking an independent seat on the board at South San Francisco-based Insitro, a specialist in applying artificial intelligence ...